Executive Team

Eduard Diviu Terradas
Eduard Diviu, BD and Eng. CEO
Co-founder and Chairman of the Board at Sagetis Biotech.With a business and engineering background, a marked entrepreneurial profile and a hands-on, science driven approach with a global view, Eduard has played a key role in the successful rise of capital since the company foundation. Eduard is also involved in the negotiations with Pharma companies and the establishment of IP strategies. He is skilful in management, human resources and setting up and executing strategic plans.
Salvador Borrós Gómez
Salvador Borrós, PhD.CSO
Co-founder and member of the Board at Sagetis Biotech. Full Professor at IQS. PhD in Chemical Engineering. Scientific Leader of Material Engineering Group (GEMAT). Member of the IQS's Bioengineering Department.Vast and proven experience, amongst others, in Materials Science (Chemistry and Chemical Engineering), Materials Science Fundamentals (Industrial Engineering), Materials Technology (Industrial Engineering), Materials Selection, Polymeric and Ceramics Materials, Biomaterials and Medical Devices (where he also holds a Master in Bioengineering).Noteworthy, he has robust knowledge and experience in Biomaterials (Stimuli sensitive polymeric nanoparticles for drug delivery; Design of biomimetic surfaces with both chemical and mechanical signalling) and Smart surfaces (Design and rapid manufacturing fabrication of scaffolds for bone and cartilage regeneration). Salvador is a cornerstone in the development and of Sagetis technology platform and the generation of intellectual property around it. He has over 110 publications and 17 patents and is in charge of the research activities carried out at Sagetis.
Xavier River Monsó
Xavier Rivero, BSc. COO and partner 
 
Seasoned professional with more than 30 years in the pharmaceutical industry, in particular in R&D and business development.Driven by passion for differentiated, innovative products that cover unmet needs. Xavier is in charge of the Development activities carried out by the company in coordination with CROs and CMOs. He has designed the Development activities that have been key for obtaining Venture Capital for the company. Xavier has been also a key figure to assess the potential risks and solutions to transform Sagetis technologies into feasible products.
Anna Cascante.jpg
Anna Cascante, PhD. R&D Director
 
PhD in Biochemistry and Molecular Biology with extensive experience in gene therapy strategies and oncology through her experience in several postdoc positions. With a pharmaceutics background and a pragmatic, down to earth approach, Anna is also the head of laboratory and a key person in the transition of the R&D candidates into formulations that can be eventually turned into medicines for human use. Anna has also several peer reviewed publications and patents.
Josep Lamarca
Josep Lamarca, MD. Chief Business Development and partner
 
MD in Neuropathology. Seasoned executive with a broad background in business development including in and out-licensing transactions. Josep has a proven track record of in and out licensing deals in both US, Japan and Europe and has a vast experience of interaction with pharma, biotech and drug delivery technology companies worldwide. Josep has also established long term relationship with pharma companies in Japan and built up partnerships with leading multidisciplinary teams in the partnering process.Besides, he has wide experience in different types of deals, from early-stage projects to commercial products, also supervising the Quality of secondary agreements. Josep has a vast experience in the preparation of in- and out-licensing strategies, and setting up internal protocols for project evaluation. He has participated as member of corporate staff, in the corporate strategic plan of a multinational pharmaceutical company. Prior to his experience in the industry, he conducted medical practice, medical education and biomedical research in neurobiology leading to original publications in the US and EU.

Advisory Board

 
Cristina Fillat
Cristina Fillat, PhD | Oncolytic adenovirus expert
Dr. Fillat is an expert in the field of gene and virotherapy. She was trained at Mount Sinai School of Medicine, in N.Y. USA during a postdoctoral stage in 1993-1994. Back to Spain she was appointed investigator at the Research Institute of Oncology (IRO) in Barcelona and started to focus its research in pancreatic cancer to explore gene and oncolytic virotherapies. In the period 2002-2011 she joined the Centre for Genomic Regulation (CRG) as a Group Leader and since 2011 she leads the Gene Therapy and Cancer Group as part of the Gastrointestinal and Pancreatic Oncology Team at the IDIBAPS. She has contributed with scientific papers with more than 90 original publications and has been PI of more than 30 research projects.
Salvador Borrós Gómez
Salvador Borrós, PhD.CSO
Co-founder and member of the Board at Sagetis Biotech. Full Professor at IQS. PhD in Chemical Engineering. Scientific Leader of Material Engineering Group (GEMAT). Member of the IQS's Bioengineering Department.Vast and proven experience, amongst others, in Materials Science (Chemistry and Chemical Engineering), Materials Science Fundamentals (Industrial Engineering), Materials Technology (Industrial Engineering), Materials Selection, Polymeric and Ceramics Materials, Biomaterials and Medical Devices (where he also holds a Master in Bioengineering).Noteworthy, he has robust knowledge and experience in Biomaterials (Stimuli sensitive polymeric nanoparticles for drug delivery; Design of biomimetic surfaces with both chemical and mechanical signalling) and Smart surfaces (Design and rapid manufacturing fabrication of scaffolds for bone and cartilage regeneration). Salvador is a cornerstone in the development and of Sagetis technology platform and the generation of intellectual property around it. He has over 110 publications and 17 patents and is in charge of the research activities carried out at Sagetis.
Robert Elfont, PhD, MD | Medical Advisor
John-Hopkins-trained neurologist with subspecialty training in neuroimmunology and neurovirology. He has over ten years in the pharma and biotech industry. Knowledgeable in all phases of clinical development, Dr. Elfont is currently managing partner at Strategic Clinical Development LLC and previously held top positions in Avigen, Roche, Pfizer and Teva.
Ramon Alemany
Ramon Alemany, PhD | Oncolytic adenovirus expert
Dr. Alemany is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has more than 80 original publications and numerous patents in the fields of Gene Therapy and Virotherapy. From 1994 to 2001, Dr. Alemany held various research positions in USA at the MD Anderson Cancer Center (Houston, TX), Baxter Healthcare (Round Lake, IL), and the University of Alabama at Birmingham. He established the Virotherapy Group at the Translational Research Laboratory of the Institut Català d'Oncologia in 2001.
Manuel Hidalgo
Manuel Hidalgo, PhD, MD | Medical Advisor
Dr. Hidalgo is an internationally renowned oncologist in the treatment of pancreatic cancer. Currently, he serves as Clinical Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center in Boston where he is also Co-Director of the Pancreatic Cancer Research Program. Dr. Hidalgo is also Professor of Medicine at the Harvard Medical School.
His ground-breaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer. This encompasses the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer. His most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalized medicine in Pancreatic Ductal Adenocarcinoma (PDAC). About 15 years ago he initiated the development of patient derived xenograft models of pancreas cancer as a platform for translational studies in this disease. Dr. Hidalgo has been the recipient of a European Research Council advanced grant.

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy